← All trials
NCT06428838
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Dec 30, 2025
- Completion date
- Dec 30, 2025
- First posted
- May 24, 2024
- Last posted
- May 24, 2024
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HealthTech Connex Inc.Lead sponsor
- University of British ColumbiaCollaborator
- HealthTech Connex Inc.Sponsor investigator
- LundbeckCollaborator
- Royal Columbian Hospital FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.